ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,695 | +2.0% | 18,097 | -2.8% | 0.18% | -39.1% |
| Q2 2023 | $1,661 | -17.1% | 18,612 | -0.4% | 0.30% | +9.8% |
| Q1 2023 | $2,003 | -6.6% | 18,678 | +6.4% | 0.28% | -15.4% |
| Q4 2022 | $2,144 | -99.9% | 17,553 | -14.1% | 0.32% | +1.6% |
| Q3 2022 | $2,109,000 | +28.8% | 20,429 | +16.0% | 0.32% | +9.6% |
| Q2 2022 | $1,637,000 | -25.9% | 17,605 | -6.5% | 0.29% | -19.3% |
| Q1 2022 | $2,209,000 | -21.0% | 18,820 | -9.5% | 0.36% | -24.1% |
| Q4 2021 | $2,797,000 | -27.4% | 20,792 | -14.0% | 0.48% | +2.1% |
| Q3 2021 | $3,853,000 | +61.1% | 24,172 | +33.0% | 0.47% | +68.6% |
| Q2 2021 | $2,392,000 | -12.5% | 18,180 | -14.3% | 0.28% | -42.7% |
| Q1 2021 | $2,734,000 | -35.2% | 21,210 | -16.2% | 0.48% | -5.7% |
| Q4 2020 | $4,222,000 | -27.7% | 25,314 | -56.5% | 0.51% | -42.9% |
| Q3 2020 | $5,839,000 | +19.0% | 58,242 | +75.6% | 0.90% | +1.7% |
| Q2 2020 | $4,905,000 | – | 33,161 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |